Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease
Woo S, Gandhi S, Ghincea A, Saber T, Lee C, Ryu C. Targeting the NLRP3 inflammasome and associated cytokines in scleroderma associated interstitial lung disease. Frontiers In Cell And Developmental Biology 2023, 11: 1254904. PMID: 37849737, PMCID: PMC10577231, DOI: 10.3389/fcell.2023.1254904.Peer-Reviewed Original ResearchSSc-ILDNLRP3 inflammasomeScleroderma-Associated Interstitial Lung DiseaseAssociated interstitial lung diseaseInterstitial lung diseaseNormal lung architectureImproved treatment optionsProgressive fibrotic replacementNovel pathophysiologic insightsComplex rheumatic diseasesImmune dysregulationPathophysiologic insightsRheumatic diseasesClinical benefitIL-18IL-1βLung diseaseTreatment optionsFibrotic replacementLung architectureNovel therapiesClinical significanceInnate immunityDiseaseAdditional studiesMitochondrial DNA-Sensing Pathogen Recognition Receptors in Systemic Sclerosis-Associated Interstitial Lung Disease: a Review
Ghincea A, Woo S, Yu S, Pivarnik T, Fiorini V, Herzog E, Ryu C. Mitochondrial DNA-Sensing Pathogen Recognition Receptors in Systemic Sclerosis-Associated Interstitial Lung Disease: a Review. Current Treatment Options In Rheumatology 2023, 9: 204-220. PMID: 38230363, PMCID: PMC10791121, DOI: 10.1007/s40674-023-00211-1.Peer-Reviewed Original ResearchToll-like receptor 9Interstitial lung diseaseLung diseaseSystemic Sclerosis-Associated Interstitial Lung DiseaseAberrant innate immune activationRecent FindingsRecent advancesCause of morbidityInnate immune activationNovel treatment approachesPathogen recognition receptorsCyclic guanosine monophosphate-adenosine monophosphate synthaseReviewSystemic sclerosisSSc patientsImmune dysregulationImmune activationReceptor 9Inflammatory fibrosisScar formationTreatment approachesRecognition receptorsDiseaseImportant unanswered questionsMechanism of releaseReviewUnanswered questions